尼达尼布联合西地那非治疗特发性肺纤维化患者
本试验将274例特发性肺纤维化且DlCO≤预测值35%的患者按1:1随机分为尼达尼布150 mg每日两次联合西地那非20 mg每日三次组或尼达尼布150 mg每日两次联合安慰剂每日三次组,治疗24周。主要终点为第12周圣乔治呼吸问卷总分较基线的变化,联合组为-1.28分,单药组为-0.77分,组间无显著差异(P=0.72)。加利福尼亚大学圣迭戈分校气短问卷评估的呼吸困难也未观察到西地那非的获益。两组均未发现新的安全性信号。
要点
- 在IPF且DlCO≤预测值35%的患者中,尼达尼布联合西地那非组第12周SGRQ总分较基线变化-1.28分,尼达尼布组-0.77分,组间无显著差异(P=0.72)。
- 加利福尼亚大学圣迭戈分校气短问卷评估的呼吸困难未观察到西地那非治疗的获益。
- 与既往试验相比,两种治疗方案均未发现新的安全性信号。
- 该人群为IPF且DlCO≤预测值35%的患者,研究疗程24周,主要终点评估时间为第12周。
适用人群与场景
- 特发性肺纤维化且DlCO≤预测值35%的患者。
处置流程与药物剂量
- 尼达尼布加西地那非组:尼达尼布150 mg每日两次口服,联合西地那非20 mg每日三次口服,疗程24周。
- 尼达尼布组:尼达尼布150 mg每日两次口服,联合安慰剂每日三次口服,疗程24周。
研究设计与关键结果
- 随机对照试验,274例患者按1:1随机分组,比较尼达尼布联合西地那非与尼达尼布联合安慰剂治疗24周。
- 主要终点第12周SGRQ总分较基线变化:联合组-1.28分 vs 尼达尼布组-0.77分,P=0.72,无显著差异。
- 加利福尼亚大学圣迭戈分校气短问卷评估的呼吸困难未观察到西地那非的获益。
- 与既往试验相比未发现新的安全性信号。
证据类型、等级与局限
- 证据类型:随机对照试验(INSTAGE,ClinicalTrials.gov NCT02802345)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在IPF且DlCO≤预测值35%的患者中,尼达尼布联合西地那非较单用尼达尼布未提供显著获益,不支持在该人群常规加用西地那非。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusion capacity of the lungs for carbon monoxide (DlCO), symptoms, and quality of life in patients with IPF and severely decreased DlCO. That idea was tested in this trial.
METHODS: We randomly assigned, in a 1:1 ratio, patients with IPF and a DlCO of 35% or less of the predicted value to receive nintedanib at a dose of 150 mg twice daily plus sildenafil at a dose of 20 mg three times daily (nintedanib-plus-sildenafil group) or nintedanib at a dose of 150 mg twice daily plus placebo three times daily (nintedanib group) for 24 weeks. The primary end point was the change from baseline in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 12 (the total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life). Secondary end points included measures of dyspnea and safety.
RESULTS: A total of 274 patients underwent randomization. There was no significant difference in the adjusted mean change from baseline in the SGRQ total score at week 12 between the nintedanib-plus-sildenafil group and the nintedanib group (-1.28 points and -0.77 points, respectively; P=0.72). A benefit from sildenafil treatment was not observed with regard to dyspnea as measured with the use of the University of California, San Diego, Shortness of Breath Questionnaire. No new safety signals were observed, as compared with previous trials.
CONCLUSIONS: In patients with IPF and a DlCO of 35% or less of the predicted value, nintedanib plus sildenafil did not provide a significant benefit as compared with nintedanib alone. No new safety signals were identified with either treatment regimen in this population of patients. (Funded by Boehringer Ingelheim; INSTAGE ClinicalTrials.gov number, NCT02802345 .).
参考来源
- Kolb M, Raghu G, Wells AU, et al. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018. PMID: 30220235. doi:10.1056/NEJMoa1811737
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。